Falk Gastro Review Journal
This page provides access to all FGR publications selected from international medical journals since mid-2022. You may browse the 1000+ articles by using one of the organ- or indication-related filters below or select all articles from a specific issue. If you are looking for ta specific journal edition, please have a look at the FGR print version.
Variation in testing for and incidence of celiac autoimmunity in Canada: A population-based study
Gastroenterology. 2023;164(4):567−78.e7
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with celiac disease after bolus exposure to gluten (RESET CeD): An interim analysis of a terminated randomized, double-blind, place-bo-controlled phase 2 study
Lancet Gastroenterol Hepatol. 2023;8(5):446−57
The efficacy of peroral endoscopic myotomy versus pneumatic dilation as treatment for patients with achalasia suffering from persistent or recurrent symptoms after laparoscopic Heller myotomy: A randomized clinical trial
Gastroenterology. 2023;164(7):1108−18.e3
Ambulatory pH-impedance findings confirm that grade B esophagitis provides objective diagnosis of gastroesoph-ageal reflux disease
Am J Gastroenterol. 2023;118(5):794−801
Esophageal hypervigilance and visceral anxiety contribute to symptom severity of laryngopharyngeal reflux
Am J Gastroenterol. 2023;118(5):786−93
Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy
Am J Gastroenterol. 2023;118(4):627−34
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)
Gut. 2023;72:1054−72
A “new” option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quad-ruple therapy in a high dual resistance setting
Helicobacter. 2023;28(3):e12962
1-food versus 6-food elimination diet therapy for the treatment of eosinophilic esophagitis: A multicenter, ran-domized, open-label trial
Lancet Gastroenterol Hepatol. 2023;8(5):408−21